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Abstract
Background: Cognitive dysfunction is common among depressed patients. However, the pattern and magnitude of 
impairment during episodes of major depressive disorder (MDD) through to clinical remission remains unclear. 
Heterogeneity of depressive patients and the lack of longitudinal studies may account for contradictory results in 
previous research.
Methods/Design: This longitudinal study will analyze cognitive differences between CORE-defined melancholic 
depressed patients (n = 60) and non-melancholic depressed patients (n = 60). A comprehensive clinical and cognitive 
assessment will be performed at admission and after 6 months. Cognitive dysfunction in both groups will be 
longitudinally compared, and the persistence of cognitive impairment after clinical remission will be determined.
Discussion: The study of neuropsychological dysfunction and the cognitive changes through the different phases of 
depression arise a wide variety of difficulties. Several confounding variables must be controlled to determine if the 
presence of depression could be considered the only factor accounting for group differences.
Background
Over the last years cognitive dysfunction has increasingly
been recognized as a core feature of major depressive dis-
order (MDD). Clinical studies have focused on the pat-
tern and magnitude of impairment during and between
episodes of MDD as well as the neuropsychological
domains affected and the origin of these abnormalities
[1]. However, results from neuropsychological and neu-
roimaging studies are still controversial. These contradic-
tory results could be explained mainly by two
methodological factors. The first factor is the absence of
homogeneity in clinical samples. The heterogeneity of
patients evaluated in clinical studies may derive from the
different criteria (DSM, ICD) currently used to diagnose
MDD and its subtypes. Some authors have pointed out
that these criteria poorly identify samples for clinical and
outcome studies [2,3]. The second factor explaining con-
troversial results is related to the lack of longitudinal
studies that focus on the changes on cognitive function
produced through the clinical course of depression.
Whether cognitive impairment manifested during peri-
ods of depression is long lasting or improves after remis-
sion and recovery remains a central issue of study [4]. The
cognitive domains affected have neither been clearly
identified [5].
To overcome the limitation derived from the first meth-
odological factor, a more acurate selection of depressed
patients is required. A pattern of cognitive dysfunction
may be more evident in a form of depression character-
ized by biological markers than in more heterogeneous
depressed samples. Melancholia is a disorder with defin-
able clinical signs that identifies more specific popula-
tions than the DSM-IV [3]. It describes episodes in which
physical symptoms are predominant and is opposed to a
reactive or non-melancholic form of depression in which
the presence of low mood and tearfulness is frequent and
biological markers are not predominant [6].
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Overcoming the limitation derived from the lack of
longitudinal data imply the development of cohort stud-
ies. Longitudinal assessment of cognitive functions seems
to be a potentially powerful method of identifying and
distinguishing state-related from trait-related cognitive
deficits [4]. Previous studies report residual neuropsy-
chological deficits in melancholic patients despite
improvement in their depressive symptomatology [7].
Particularly, persisting executive functions and memory
disturbances have been observed. This would indicate
that some cognitive dysfunction may not be simply sec-
ondary to mood disturbances in depression but may rep-
resent trait vulnerability markers for MDD. Deficits in
other domains of cognitive performance appear to be
more state-dependent [8]. The high risk of relapse in
depression makes it important to analyze the existence of
persisting cognitive impairments during remission,
recovery and the euthymic phase of depression. A better
understanding of these issues is crucial as it has been sug-
gested that cognitive impairment worsens for every epi-
sode of depression and that the observed cognitive
impairment in a nonsymptomatic phase of depression
may be related to the number of previous episodes [9].
The course of cognitive changes through to clinical
improvement in samples of depressed participants with
and without melancholia has scarcely been longitudinally
studied [6]. The present study aims to analyze longitudi-
nally the cognitive performance of a homogeneous sam-
ple of depressed patients. Results of this study can have
relevant implications for treatment and neuropsychologi-
cal rehabilitation.
Methods/Design
Objectives
The general aim of this study is to analyze cognitive dif-
ferences between melancholic depression (MD) and non-
melancholic depression (NMD), and compare longitudi-
nally the cognitive dysfunction in both types of patients,
determining whether these alterations remain after clini-
cal remission. This will enable to define a specific cogni-
tive dysfunction pattern depending on these subtypes of
depression. Finally, the study will analyze the correlation
between the severity of these dysfunctions and the num-
ber of previous depressive episodes.
Our hypotheses are that specific cognitive deficits dur-
ing acute phase of MDD will be different between
patients with MD and NMD. Melancholic depressed
patients are expected to show a poorer performance on
memory, attention and executive function tasks at base-
line. We hypothesize that cognitive deficits in the group
with melancholia will persist at the follow-up assessment
despite the presence or absence of clinical remission.
Cognitive deficits in the non-melancholic depression
group will only be expected to persist in those patients
who fail to achieve clinical remission at the 6-month fol-
low-up assessment while is presumed to be reduced or to
disappear in those who have achieved it. Finally, the num-
ber of previous episodes of depression of melancholic
patients is predicted to positively correlate with cognitive
deficits severity.
Design
This is a multicenter, observational longitudinal cohort
study that will include 120 outpatients treated for an
acute episode of MDD. 60 patients with melancholic
depression will be compared to 60 non-melancholic
depressed patients matched by age, gender and education
level. All patients will be included during an acute phase
of the disorder and will undertake standard psychophar-
macological treatment for depression.
Information regarding socio-demographic and clinical
features will be collected at the baseline evaluation. A
neuropsychological protocol will be administrated both
at the baseline and the six-month follow-up assessments.
The obtained results will be compared between four
groups: melancholic patients showing clinical remission,
melancholic patients who fail to achieve clinical remis-
sion, non-melancholic patients showing clinical remis-
sion and, finally, non-melancholic patients who fail to
achieve clinical remission.
In our study clinical remission will be operatively con-
ceptualized as having a HDRS total score ≤ 7 both at the
6-month follow-up assessment and in an additional inter-
view that will be performed two weeks later.
This study will be performed in accordance with the
Helsinki Declaration of the World Medical Association
Assembly and the Madrid Declaration of the World Psy-
chiatric Association (WPA). The study protocol has
received the approval of the Ethics and Clinical Research
Committee of the Balearic Islands (Palma de Mallorca,
Spain).
Setting
All patients will be identified and recruited from different
centers across the island of Majorca (Spain), including 4
Outpatient Psychiatric Units (Joan March Hospital, Son
Dureta Hospital, Son Llàtzer Hospital and Hospital of
Manacor), 2 Mental Health Units and 9 Primary Care
Centers.
Measuraments
1. Sociodemographic and clinical questionnaire 
designed specifically for this study. Relevant sociode-
mographic information regarding gender, date of 
birth and age, marital status, education level and 
occupational status, as well as clinical data regarding 
age of disorder onset, number of previous episodes 
and current pharmacological treatment (type of Monzón et al. BMC Psychiatry 2010, 10:48
http://www.biomedcentral.com/1471-244X/10/48
Page 3 of 7
agent, mean dose and time of administration) will be 
collected.
2. DSM-IV criteria for Major Depressive Disorder 
[10].
3. 17-item Hamilton Depression Rating Scale 
(HDRS) [11]. This is the most commonly used sever-
ity scale in clinical practice and research with mood 
disorders [12,13].
4. The CORE system for melancholia (CORE) [14] is 
an 18-item scale which assesses features of melan-
cholic depression such us retardation, agitation and 
non-interactivity by behavioural observation. Each 
sign is rated on a 4-point scales (0-3) by clinicians or a 
trained observer. The CORE distinguish melancholia 
from other residual depressive disorders. Depressed 
patients will be allocated to the CORE-defined mel-
ancholic group if they store 8 or more. The Spanish 
version of this scale is currently under validation. Our 
group is involved in this process.
5. The Mini-Mental State Examination (MMSE) 
[15] has been widely used as a screening tool both in 
clinical practice and in research. The MMSE total 
score is widely accepted as an indicator of the severity 
of cognitive impairment. It is highly sensitive (87%), 
and highly specific (82%) in the detection of demen-
tia. The success of the MMSE relay on the fact that it 
can be admistered in a very short time. It is able to 
objectify cognitive status as a single global score and 
to track decline from mild to severe dementia.
6. The Clinical Global Impression rating scales 
(CGI-S, CGI-I) [16] are commonly used measures of 
symptom severity, treatment response and efficacy of 
treatments in treatment studies of patients with men-
tal disorders. The Clinical Global Impression - Sever-
ity scale (CGI-S) is a 7-point scale that requires the 
clinician to rate the severity of the patient's illness at 
the time of assessment, relative to the clinician's past 
experience with patients who have the same diagno-
sis. The Clinical Global Impression - Improvement 
scale (CGI-I) is a 7 point scale that requires the clini-
cian to assess how much the patient's illness has 
improved or worsened relative to a baseline state.
Cognitive assessment, administered in this fixed order:
1. Trail Making Test-Parts A and B [17] In this test 
the subject consecutively connects numbered circles 
(Trails A) and then connects numbers and letters in 
alternating sequence (Trails B). Both are timed tests 
of visuomotor speed, with Trails B also being a test of 
set-switching. A high score indicates poor perfor-
mance. Results from a recent study [18] suggest that 
TMT-A requires mainly visuoperceptual abilities 
whilst TMT-B reflects primarly working memory and 
secondarily task-switching ability. The difference 
score B-A would minimize visuoperceptual and work-
ing memory demands, providing a relatively pure 
indicator of executive control abilities.
2. Digit Span subtest of the Weschler Adult Intelli-
gence Scale, 3rd edition (WAIS-III) [19]. Digit span 
forwards is used as a measure of attention and phono-
logical storage in working memory whilst digit span 
backwards also draws on mental flexibility and is 
additionally regarded as a measure of executive func-
tion [20].
3. Stroop Colour Word Test (SCWT) [21]. This task 
measures selective attention, freedom from distracti-
bility and response inhibition [20]. Three 45-second 
trials are used in this test where the subject is asked to 
read out three colour names printed in black ink as 
fast as posible. The subject then is presented with the 
same words printed in a colour different from the 
color which it names. The subject is instructed to 
name, as fast as posible, the colour of the ink in which 
the word is printed. The time taken to complete the 
task increases significantly under these conditions 
and thi is called the 'interference effect'. The interfer-
ence score is calculated by substracting Trial 1 (nam-
ing words) from Trial 3 (stating the colour in which 
the word is printed), a higher score indicating greater 
interference.
4. Tower of London, 2nd Edition (TOL-DX) [22]. 
This is a test of planning that taxes central executive 
function. Subjects rearrange a set of spheres to match 
a given target arrangement in a specified number of 
moves. Accuracy and latency are recorded [23].
5. The Controlled Verbal Fluency Task (FAS) [24]. 
This is a timed test in which the subject is asked to 
generate words starting with letters F, A and S as fast 
as posible. This task involves development of a strat-
egy to produce the words and is dependent on psy-
chomotor speed. A standard score of 12 words 
beginning with a specific letter is expected to be pro-
duced within 1 minute.
6. Semantic Verbal Fluency (ANIMALS). This test 
requires the generation of words corresponding to a 
specific semantic category. The number of correct 
words in one minute is counted. A mean of 16 words 
is expected to be produced as a standard score [25].
7. Finger Tapping Test (FTT) [26]. Originally devel-
oped as part of the Halstead Reitan Battery (HRB) of 
neuropsychological tests, the Finger Tapping Test is a 
simple measure of motor speed and motor control. 
The speed, coordination and pacing requirements of 
finger tapping can be affected by levels of alertness, 
impaired ability to focus attention, or slowing of 
responses.
Study sample
The recruitment strategy will be performed by General
Practicioners and Psychiatrists involved in the study. AnyMonzón et al. BMC Psychiatry 2010, 10:48
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outpatient who might fulfil all the inclusion criteria will
be offered to participate in the study. Male and female
outpatients who are eligible and sign the written
informed consent will be entered into the study.
At the screening interview the Hamilton Depression
Rating Scale (HDRS) will be used to determine depres-
sion severity while the CORE Scale [27] will allow distin-
guishing melancholic depressive patients (MD) from
non-melancholic depressive patients (NMD). Inclusion
criteria are: a diagnosis of DSM-IV unipolar MDD, to be
under treatment with antidepressive agents or to initiate
this treatment, age between 18-55 years, a HDRS greater
than or equal to 18, a total score greater or equal to 8 in
the CORE scale for the Melancholic Depression patients
and under 8 for the non-melancholic depression individ-
uals and enough capacity for understanding and signing
the written informed consent form. Exclusion criteria are:
history of medical conditions that can entail cognitive
deterioration, history of head injury or neurological dis-
order, current psychotic symptoms, current treatment
with antipsychotic or mood stabilizer agents, electrocon-
vulsive therapy in the 6 months prior to the study; a diag-
nosis of mental retardation, and disability to understand
and complete the cognitive assessment.
Procedure
Clinical interview will be performed both at baseline and
follow-up assessments. The structured clinical interview
will address sociodemographic characteristics, medical
history and current medication prescription. Clinical
scales and questionnaires will also be administrated. The
cognitive assessment will follow the clinical interview. It
will also be conducted at baseline and 6 months later. The
follow-up assessment will take place after 6 month of
inclusion in the study independently of the patient clini-
cal state (acute phase, clinical remission or recovery). All
patients showing a HDRS total score ≤ 7 in the follow-up
assessment will be re-interviewed after two weeks. They
w i l l  be  c o n s i d e r ed  a s  be i n g  i n  r e m i s s i o n  o f  d e p r e s s i v e
symptoms if the HDRS total score at this time remains
equal or under 7 points. All assessments will be per-
formed by two trained psychologists (SM, MV), and will
be carried out in the morning in order to avoid the con-
founding effects of diurnal fluctuation in mood and corti-
sol levels which have been pointed out to influence
cognitive performance [28].
Description of all comparisons
Obtained data regarding sociodemographic and clinical
features of the depresive episode at baseline assessment
will be compared between melancholic and non-melan-
cholic depressed patients in order to detect any signifi-
cant difference.
Intergroup analysis will provide information regarding
test score differences between melancholic and non-mel-
ancholic depressed patients both at baseline and the fol-
low-up assesments. Furthermore, comparisons between
melancholic and non-melancholic depressed patients
showing clinical remission will be carried out. Melan-
cholic and non-melancholic depressed patients who fail
to achieve clinical remission will be compared as well.
Intragroup comparisons will provide information
regarding test score differences between the baseline and
the follow-up assessment for each group. Thus, the cog-
nitive profile of melancholic depressed patients at base-
line will be compared to the cognitive profile obtained at
follow-up assessment and the cognitive profile of non-
melancholic patients will be compared likewise. Test
scores obtained by melancholic depressed patients who
show clinical remission will be compared at both times of
assessment. Test scores of non-melancholic depressed
patients showing clinical remission will be compared like-
wise. The same comparisons will be undertaken with
melancholic and non-melancholic depressed patients
who fail to achieve clinical remission.
Statistical Analyses
Obtained data will be analyzed with the Statistical Pack-
age for the Social Sciences (SPSS) version 17. Univariate
descriptive analysis of the included variables will be per-
formed. For metric variables, central tendency measures,
measures of statistical dispersion and measures of posi-
tion will be applied. In the case of categorical variables,
univariate description will be obtained with relative fre-
quencies. Bivariate analysis will be performed by means
of the Student's t-test for the comparison of two means,
the Analysis of Variance (ANOVA) for the mean compar-
ison of more than two groups, the Mann-Whitney test for
ordinal variables and the Chi-square test for categorical
variables. Multivariate analysis will be calculated with
multiple linear regression and logistic regression models.
Type of analysis
The sample size was calculated assuming an alpha risk of
0.05 and accepting a beta error rate of 20%, which corre-
sponds to a study power of 80%. Expecting a 20% loss, the
necessary sample size will be 60 patients in each group,
constituting thus a total sample of 120 patients.
Discussion
To our knowledge, this will be the first study design that
longitudinally compares cognitive functioning in
depressed patients with and without CORE-defined mel-
ancholic features. The imprecision of depressive symp-
toms limit the capacity of any measure to delineate and
measure melancholia [29]. Nowadays, there is no a goldMonzón et al. BMC Psychiatry 2010, 10:48
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standard measure of melancholia. However, while other
measures such as the Newcastle and the Hamilton
Depression Rating Scale essentially generate depression
severity scores, the CORE scores seems to be sufficient to
the clinical definition of melancholia [2].
In the present study, the cognitive profile of those
patients showing clinical remission of depressive symp-
toms will be separately analyzed from the cognitive pro-
f i l e  o f  t h o s e  p a t i e n t s  w h o  f a i l  t o  a c h i e v e  r e m i s s i o n  o f
symptoms. The design seeks to overcome two important
methodological limitations of previous investigation: the
heterogeneity of depressed patients samples and the lack
of longitudinal studies focusing on cognitive functioning
changes from the acute phase of depression to clinical
remission.
The study of neuropsychological dysfunction and the
cognitive changes through the different phases of depres-
sion arise a wide variety of problems. Some of them are
closely related to the nature and intrinsic characteristics
of neuropsychological assessment and the interpretation
of results. Most of the neuropsychological tests that will
be used in our study were primarily developed for brain-
damaged patient examination. As highlighted by Austin
et al. [30], the application of this tests to patients with
functional psychiatric disorders calls for caution in inter-
preting test results. It is also important to recognize that
test complexity adds more difficulty to the interpretation
of findings. Many neuropsychological tests involve a
number of complex cognitive processes. Few (if any)
measure only one circumscribed cognitive function and it
has been suggested that assigning tests to specific cogni-
tive categories is somewhat arbitrary [1].
Another major difficulty is related to the wide variety of
confounding variables that must be controlled in neurop-
sychological testing. The presence of depression should
be the only difference likely to impact on cognitive func-
tion [1]. Difference in neuropsychological function not
attributable to depression could be explained by differ-
ences between groups in variables such as gender, age,
severity of depression, antidepressant treatment type and
number of previous episodes, among others.
Gender
Few studies of neuropsychological impairment in MDD
have considered the effects of gender on cognitive perfor-
mance [1]. The present study will apply no restrictions
regarding gender for inclusion, although according to
some authors, there would be a gender-related specificity,
since depressed women appear to perform significantly
worse as compared with depressed men [31]. However,
gender will be taken into account as a covariate in statisti-
cal analysis.
Age
Age is associated with a progressive decline in cognitive
function. Difficulties produced by age (such as mental
inflexibility, higher susceptibility to distractors and perse-
veration) [32] involve the same specific domains that are
impaired in more severe (and melancholic-type) depres-
sion. Most of the studies investigating the association
between depression and cognitive dysfunction have been
conducted among middle-aged and elderly patients or
among patients regardless of their age [8]. In any study of
cognitive deficits in depression, episodes of depression
that occurs for the fist time in later life should be consid-
ered as a potential confounder. It has been demonstrated
that there is a greater contribution of the vascular pathol-
ogy in late-onset cases of depression [33]. Although there
is no consensus regarding the age of onset cut-off for late-
onset depression [34], it is generally established as later
than age 60. Therefore, in our study a cut-off age of 55
years was established in order to clearly exclude possible
cases of late-onset depression and to avoid any other sig-
nificant age-related confounders.
Severity of depression
Many studies have investigated the effect of severity of
depression on neurocognitive task performance. Overall,
results suggest the importance of applying corrections for
depression severity when comparing patients with differ-
ent subtypes of MDD, as it seems quite clear that differ-
ences in mean depression scores of patient samples could
account in part for the different levels and patterns of
cognitive impairment observed [35]. In fact, there are no
studies investigating the relationship between melancho-
lia and neuropsychological impairment showing a defini-
tively different pattern unrelated to measures of severity.
Antidepressant treatment type
The use of medication during neuropsychological assess-
ment is an important confounding variable. It is therefore
surprising that most of the works studying the persis-
tence of cognitive disturbances beyond the symptomatic
phase of MDD have overlooked the possible impact of
medication on cognitive function [36]. Antidepressant
(especially tricyclic antidepressant) and benzodiazepines
can deteriorate performance due to their effects on cog-
nitive and motor functions. Many antidepressants exhibit
pharmacological properties that can explain why such
dysfunctions should be expected. However, some works
have shown that antidepressants can also improve perfor-
mance, possibly due to its positive effect on mood [37].
Indeed, improvement in memory and attention skills in
depressed patients treated with selective serotonine
reuptake inhibitors (SSRI) such as fluoxetine or parox-
etine have been described [38].Monzón et al. BMC Psychiatry 2010, 10:48
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Control for the potential effects of medication will be
applied in our study by establishing treatment type as a
covariate in statistical analysis. Electroconvulsive therapy
received in the six months preceding study admission was
established as an exclusion criteria.
Number of previous episodes
Little is known regarding the influence of age of onset,
duration and number of episodes of MDD on cognitive
function in depressed patients. A great part of the studies
concerning number of episodes and cognitive perfor-
mance in depression have mainly been related to memory
rather than to attention or executive functions [4]. Some
studies have pointed out that there would be a worsening
on cognitive function for every episode of depression
[39,40].
C) Strenghts and limitations
Among the strengths of this study it must be highlighted
the large number of participants to be included as well as
the homogeneity of the sample of depressed patients,
especially with respect to their melancholic or non-mel-
ancholic condition. We have applied a narrow definition
of melancholia (measured by the CORE system) instead
of the broad definition of the DSM which, although being
' t h e  m o s t  f r e q u e n t l y  u s e d '  r e f e r e n c e  p o i n t ,  h a v e  b e e n
pointed out to have poor agreement with the core fea-
tures of melancholia derived from empirical studies [41].
As noted above, only few studies have compared cogni-
tive performance in melancholic MDD patients longitu-
dinally. However, it has been suggested that a measure of
chronic depressive symptoms taken over a period of time
may share a closer relationship with cognitive function
[35].
Another major strength of the present study is related
to the conceptualization of remission in depression.
Establishing a standarized definition of remission is a
controversial issue. According to most definitions, it is
described as a state of minimal to no symptoms and a
return to normal functioning [42]. Most studies have usu-
ally conceptualized remission without establishing a spe-
cific duration criterion. To many authors, this seems to be
an inappropriate way to operatively conceptualize remis-
sion, as longitudinal assessment is required [43]. Thus, in
our study clinical remission will be conceptualized as
having a HDRS total score ≤ 7 both at the 6-month fol-
low-up assessment and at an additional assessment that
will be carried out two weeks later.
The number of significant confounders in neuropsy-
chological testing is high. However, control of a variety of
confounders such as gender, age or type of treatment
among others will be applied.
The present study shows some limitations as well.
Although the neuropsychological assessment is compre-
hensive, not every cognitive function will be assessed.
Patients using other medication different to antidepres-
sants or benzodiazepines will be excluded. So will be
patients who have received electroconvulsive therapy in
the six months previous to screening for this study. This
could limit somehow the extent of results' applicability.
Another possible limitation is that the presence of
comorbid Axis I, Axis II or Axis III DSM-IV disorders
will not be taken into account. Although it is possible that
in some way this could increase the cognitive impairment
a s s o c i a t e d  w i t h  M D D ,  e v e r y d a y  p r a c t i c e  s h o w s  t h a t
comorbidity is not uncommon and exclusion of patients
due to comorbid disorders could limit generalisability of
results. All eligible patients with a history of medical con-
ditions that could entail cognitive deterioration or with a
history of head injury or neurological disorder will be
excluded. However, it is possible that some of the patients
that will be included in the study may present clinical
symptoms of an incipient undiagnosed clinical picture.
This possibility must be taken into account and calls for
caution in the interpretation of results.
Findings of the present study will contribute to bring
light to the melancholic subtype of depression debate.
Moreover, they may help to identify differential neu-
rocognitive profiles between those depressed patients
who remit and those who do not achieve remission and
would give rise to future research of specifically tailored
treatments.
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